Cisplatin 병합 화학요법에 의한 오심 및 구토에서 Ondansetron의 효과에 대한 연구
Efficacy of Ondansetron is Cisplatin-Induced Nausea and Vomiting
대한암학회지 1993년 25권 6호 p.975 ~ 981
소속 상세정보
김금정
김정백/김광미/박정숙/박순희/김시영/윤휘중/조경삼
KMID : 0360319930250060975
Abstract
Ondansetron(GR 38032F) is an antiemetic agent with a selective antagonistic action to serotonin S3 receptors, devoid of anti-dopaminergic property.
The effects of ondansetron in control of nausea and emesis induced by cisplatin containing chemotherapy regimen were compared to those of formerly used antiemtic agents, MDL (metoclopramide, dexamethasone, lorazepam combination) therapy.
Ondansetron was given to the patient, who had vomiting in first and second cycle of chemotherapy containing cisplatin with MDL therapy. It was administered intravenously 15 min before and 4 hours and 8 hours after cisplatin administration, then
given
orally every 12 hour up to 24 hours after end of chemotherapy. No other antiemetics were used.
Major control(complete and near complete) of emesis was achieved in 2 of 30(6.7%) patients receiving ondansetron and in 4 of 30(13.3%) patients receiving MLD. For acute emesis, major control was achieved in 24 of 30(80.0%) patients with
ondansetron. For
delayed emesis, major control was achieved in 3 of 30(10.0%) patients with ondansetron. No severe side reaction was seen in patients receiving ondansetron, while transient elevations in aspartate or alanine aminotransferase level were observed in
10
patients.
In conclusion, ondansetron was safe and effective in controlling the acute emesis, comparable to MDL therapy, but was less effective in controlling delayed emesis.
키워드
원문 및 링크아웃 정보
등재저널 정보